Travere Therapeutics, Inc.

NasdaqGM:TVTX Stock Report

Market Cap: US$1.5b

Travere Therapeutics Management

Management criteria checks 2/4

Travere Therapeutics' CEO is Eric Dube, appointed in Jan 2019, has a tenure of 5.92 years. total yearly compensation is $7.57M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $2.07M. The average tenure of the management team and the board of directors is 4.2 years and 7.7 years respectively.

Key information

Eric Dube

Chief executive officer

US$7.6m

Total compensation

CEO salary percentage10.5%
CEO tenure5.9yrs
CEO ownership0.1%
Management average tenure4.2yrs
Board average tenure7.7yrs

Recent management updates

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Recent updates

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Dec 19

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Oct 31
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Shares Bounce 27% But Its Business Still Trails The Industry

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Oct 07
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN

Sep 30

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Sep 10
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Travere Therapeutics: Judgement Day Is Nigh For Sparsentan

Aug 30

Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

May 02
Shareholders May Be More Conservative With Travere Therapeutics, Inc.'s (NASDAQ:TVTX) CEO Compensation For Now

Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Apr 20
Lacklustre Performance Is Driving Travere Therapeutics, Inc.'s (NASDAQ:TVTX) 29% Price Drop

Travere Therapeutics: Restructuring Away From Disaster

Jan 30

Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 22
Travere Therapeutics (NASDAQ:TVTX) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

Dec 18
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Share Price Boosted 48% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Aug 08
New Forecasts: Here's What Analysts Think The Future Holds For Travere Therapeutics, Inc. (NASDAQ:TVTX)

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Jun 09
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

May 05
It's Down 27% But Travere Therapeutics, Inc. (NASDAQ:TVTX) Could Be Riskier Than It Looks

Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Feb 16
Is Travere Therapeutics (NASDAQ:TVTX) A Risky Investment?

Travere Therapeutics' FDA target action date for nephropathy treatment extended

Oct 13

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Oct 06
Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Travere Therapeutics: Changes In The Risk-Reward Assessment

Sep 29

Travere, CSL kidney disease drug sparsentan gets review in EU

Aug 22

Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M

Aug 04

Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'

Jul 14

Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

Jun 19
Is Travere Therapeutics (NASDAQ:TVTX) Weighed On By Its Debt Load?

CEO Compensation Analysis

How has Eric Dube's remuneration changed compared to Travere Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$349m

Jun 30 2024n/an/a

-US$383m

Mar 31 2024n/an/a

-US$416m

Dec 31 2023US$8mUS$796k

-US$376m

Sep 30 2023n/an/a

-US$373m

Jun 30 2023n/an/a

-US$368m

Mar 31 2023n/an/a

-US$352m

Dec 31 2022US$6mUS$747k

-US$331m

Sep 30 2022n/an/a

-US$297m

Jun 30 2022n/an/a

-US$249m

Mar 31 2022n/an/a

-US$202m

Dec 31 2021US$6mUS$708k

-US$217m

Sep 30 2021n/an/a

-US$250m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$224m

Dec 31 2020US$5mUS$661k

-US$169m

Sep 30 2020n/an/a

-US$78m

Jun 30 2020n/an/a

-US$92m

Mar 31 2020n/an/a

-US$105m

Dec 31 2019US$10mUS$618k

-US$146m

Compensation vs Market: Eric's total compensation ($USD7.57M) is above average for companies of similar size in the US market ($USD5.54M).

Compensation vs Earnings: Eric's compensation has increased whilst the company is unprofitable.


CEO

Eric Dube (51 yo)

5.9yrs

Tenure

US$7,574,959

Compensation

Dr. Eric M. Dube, Ph D., serves as an Independent Director at Reneo Pharmaceuticals, Inc. since March 2021. Dr. Dube serves as President and Chief Executive Officer at Travere Therapeutics, Inc. (formerly...


Leadership Team

NamePositionTenureCompensationOwnership
Eric Dube
President5.9yrsUS$7.57m0.14%
$ 2.1m
Christopher Cline
Chief Financial Officer2.3yrsUS$1.97m0.086%
$ 1.3m
Elizabeth Reed
Senior VP7.9yrsUS$2.02m0.090%
$ 1.4m
William Rote
Senior VP and Head of Research & Development7.8yrsUS$2.05m0.041%
$ 611.6k
Peter Heerma
Chief Commercial Officer5.2yrsUS$2.00m0.068%
$ 1.0m
Sandra Calvin
SVP, Corporate Controller & Chief Accounting Officer3.3yrsno data0.063%
$ 943.7k
Nivi Nehra
Vice President of Corporate Communications & Investor Relationsno datano datano data
Angela Giannantonio
Senior Vice President of Human Resourcesno datano datano data
Casey Logan
Chief Business Officerless than a yearno datano data
Jula Inrig
Chief Medical Officer2.9yrsUS$2.87m0.071%
$ 1.1m
Charlotte Smith
Senior Vice President of Public Affairsno datano datano data

4.2yrs

Average Tenure

52yo

Average Age

Experienced Management: TVTX's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Eric Dube
President5.9yrsUS$7.57m0.14%
$ 2.1m
John Orwin
Independent Director7.8yrsUS$372.98k0.033%
$ 496.1k
Gary Lyons
Independent Chairman of the Board10.2yrsUS$392.98k0.059%
$ 876.2k
Stuart J. Swiedler
Member of Scientific Advisory Boardno datano datano data
Suzanne Bruhn
Independent Director4.7yrsUS$372.36k0.026%
$ 382.2k
Roy Baynes
Independent Director8.5yrsUS$376.73k0.036%
$ 532.6k
Ruth Williams-Brinkley
Independent Director3.3yrsUS$365.48k0.022%
$ 330.7k
Timothy Coughlin
Independent Director9.8yrsUS$385.48k0.056%
$ 841.8k
Ron Squarer
Independent Director7.7yrsUS$367.98k0.033%
$ 496.1k
Jeffrey Meckler
Independent Director10.2yrsUS$379.98k0.093%
$ 1.4m
Alan Beggs
Member of Scientific Advisory Boardno datano datano data
Sandra Poole
Independent Director5.6yrsUS$369.86k0.027%
$ 403.7k

7.7yrs

Average Tenure

60yo

Average Age

Experienced Board: TVTX's board of directors are considered experienced (7.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:03
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Travere Therapeutics, Inc. is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Guyn KimBMO Capital Markets Equity Research
Gregory HarrisonBofA Global Research
Jason ZemanskyBofA Global Research